[Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist].
Anakinra, a recombinant human interleukin-1 receptor antagonist offers a new potent treatment for rheumatoid arthritis(RA). It is administered as a daily single subcutaneous injection. Recent randomized, double-blind, placebo-controlled trials revealed that anakinra significantly reduces the signs and symptoms of RA, reduces joint destruction, and is safe and tolerated. It was also revealed that anakinra is more potent when used in combination with methotrexate.
Suzuki
Takeshi
T
Department of Allergy and Rheumatology, Graduate School of Medicine, University of Tokyo.
D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein; D008727:Methotrexate / Q000627:therapeutic use*; D012795:Sialoglycoproteins / Q000627:therapeutic use*
C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D012795:Sialoglycoproteins; D008727:Methotrexate